Aelis Farma says IDMC flags no safety issues, backs continuing AEF0217 Phase 2b Down syndrome trial

• Aelis Farma’s independent monitoring committee recommended continuing the Phase 2b AEF0217 trial in Down syndrome with no protocol changes.
• The blinded safety review found no serious or severe adverse events; reported events were mild, none judged treatment-related; no discontinuations for adverse events.
• Enrollment reached 65 randomized participants, with 188 planned; recruitment completion targeted by end-2026; results expected by end-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aelis Farma SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.